In the Phase 3 PATINA trial, Pfizer's IBRANCE® combined with standard treatments improved median progression-free survival by more than 15 months in patients.

This study was a Phase 2 trial assessing two doses of its unique selective cortisol modulator, dazucorilant, in patients diagnosed with ALS.

Galderma has obtained FDA approval in the U.S. for Nemluvio® (Nemolizumab) aimed at treating patients with moderate to severe atopic dermatitis.

Antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs), as vital components of precision medicine, have demonstrated tremendous potential in the field of gene therapy.

Bicycle Therapeutics reveals new data on its Zelenectide Pevedotin initiative and plans to enhance development based on NECTIN4 gene amplification.

Among the many immune checkpoint inhibitors, Durvalumab (brand name Imfinzi) stands out as particularly noteworthy.

Candel Therapeutics reports that CAN-2409 met its main goal in a Phase 3 trial for prostate cancer, demonstrating a notable increase in disease-free survival.

Astria Therapeutics reports successful final outcomes from the target enrollment of the ALPHA-STAR Phase 1b/2 trial of Navenibart for HAE.

Arrowhead Pharmaceuticals shares preliminary clinical findings on ARO-CFB for treating complement-mediated conditions.

In the OlympiA Phase III trial, LYNPARZA® (olaparib) showed a significant increase in survival for early breast cancer patients.

Caliway reports positive outcomes from CBL-0204, a Phase 2b trial of CBL-514 aimed at decreasing abdominal subcutaneous fat, achieving all key efficacy goals.

Accent Therapeutics has initiated dosing for the first patient in its Phase 1/2 trial of ATX-559, alongside a change in its Chief Scientific Officer.